| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| 2g | |||
| Other Sizes |
| Targets |
Scopine hydrochloride targets muscarinic acetylcholine receptors (mAChRs) as an active metabolite of scopolamine. It is also a metabolite of anisodine, which is an α1-adrenergic receptor agonist. Its binding to muscarinic receptors is thought to contribute to its anticholinergic effects. It may also interact with α1-adrenergic receptors, although its primary pharmacological activity is related to its role as a scopolamine metabolite.
|
|---|---|
| ln Vitro |
In vitro, Scopine hydrochloride is the metabolite of anisodine, which is a α1-adrenergic receptor agonist. It is an active metabolite of the muscarinic acetylcholine receptor (mAChR) antagonist scopolamine. As a metabolite, it may retain some of the pharmacological activity of its parent compounds. Quantitative in vitro activity data, such as IC50 or Ki values for receptor binding, is not detailed in the publicly available sources.
|
| ln Vivo |
In vivo, Scopine hydrochloride significantly increases the brain exposure of Chlorambucil and enhances its anti-glioma activity. This suggests that it may have utility as a pharmacokinetic enhancer or adjuvant in cancer therapy. Its role as a metabolite of scopolamine and anisodine indicates that it may contribute to the pharmacological effects of these drugs in vivo.
|
| Enzyme Assay |
For cell-free assays, the binding affinity of Scopine hydrochloride to muscarinic and adrenergic receptors can be measured using radioligand binding assays. Membrane preparations from cells expressing the receptors are incubated with a radiolabeled ligand specific for the receptor and varying concentrations of Scopine hydrochloride. Ki values are calculated from competition binding curves.
|
| Cell Assay |
For in vitro cellular assays, the activity of Scopine hydrochloride at muscarinic and adrenergic receptors can be assessed in cells expressing these receptors. Cells are treated with the compound, and its effect on receptor-mediated signaling, such as calcium mobilization or cAMP accumulation, is measured. Its ability to modulate the uptake or efflux of other drugs, such as Chlorambucil, can also be studied.
|
| Animal Protocol |
For in vivo studies, Scopine hydrochloride could be administered orally or intraperitoneally in animal models of glioma to assess its ability to enhance the brain penetration and anti-tumor activity of Chlorambucil. Its pharmacokinetic profile, including its ability to cross the blood-brain barrier, can be studied. Its effects on the central nervous system, related to its anticholinergic activity, could also be evaluated.
|
| ADME/Pharmacokinetics |
Scopine hydrochloride (CAS 85700-55-6) has a molecular formula of C8H14ClNO2 and a molecular weight of 191.66 g/mol. Its IUPAC name is (1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-ol;hydrochloride. Appearance: typically a solid. Solubility: DMSO and other solvents. Storage: 2-8°C. Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a tropane alkaloid and metabolite of scopolamine, it may have anticholinergic side effects at high doses, such as dry mouth, blurred vision, and sedation. However, its toxicity profile is likely similar to that of other tropane alkaloids. Standard toxicological studies would be required for drug development.
|
| Additional Infomation |
Scopine hydrochloride is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying muscarinic and adrenergic receptors, and as a metabolite standard. Its mechanism of action involves interaction with mAChRs and α1-adrenergic receptors. It is used in the synthesis of antispasmodic, antiemetic, and anti–motion sickness agents. No clinical trials have been reported.
|
| Molecular Formula |
C8H14CLNO22
|
|---|---|
| Molecular Weight |
191.6553
|
| Exact Mass |
191.071
|
| Elemental Analysis |
C, 50.14; H, 7.36; Cl, 18.50; N, 7.31; O, 16.70
|
| CAS # |
85700-55-6
|
| Related CAS # |
Scopine; 498-45-3
|
| PubChem CID |
24720972
|
| Appearance |
Solid powder
|
| Melting Point |
207-213ºC
|
| LogP |
0.331
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
179
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN1[C@@H]2C[C@H](C[C@H]1[C@@H]1O[C@@H]12)O.Cl
|
| InChi Key |
BBBRAOXIMQHVCR-QYRWGYAXSA-N
|
| InChi Code |
InChI=1S/C8H13NO2.ClH/c1-9-5-2-4(10)3-6(9)8-7(5)11-8;/h4-8,10H,2-3H2,1H3;1H/t4?,5-,6+,7-,8+;
|
| Chemical Name |
(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-ol;hydrochloride
|
| Synonyms |
Scopine HCl; Scopine Hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (~521.8 mM)
DMSO: ~25 mg/mL (~130.4 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (521.76 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2176 mL | 26.0879 mL | 52.1757 mL | |
| 5 mM | 1.0435 mL | 5.2176 mL | 10.4351 mL | |
| 10 mM | 0.5218 mL | 2.6088 mL | 5.2176 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
